Pharmaceutical Canada's Labopharm and privately-owned Gruppo Angelini of Italy have entered into an agreement to establish a joint venture in the USA for the commercialization of Oleptrol (trazodone HCl) extended release tablets, a novel once-daily formulation of the antidepressant trazodone approved by the US Food and Drug Administration on February 3 this year. The JV, Angelini Labopharm, will be 50% owned by each partner and will be initially managed by Mary Anne Heino, president of Labopharm's US Operations, and her team. 4 May 2010